AC Immune claims half a win for tau drug in Alzheimer’s trial
pharmaphorum
AUGUST 31, 2021
Shares in AC Immune leaped today after the company said its tau-targeting Alzheimer’s disease candidate semorinemab hit one of its objectives in a phase 2 trial, although it missed another. Roche’s Genentech unit bought into the programme in 2012 and amended it three years later.
Let's personalize your content